Cargando…

LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA

Pilocytic astrocytomas (PA) are low-grade gliomas (pLGG) and are the most frequent childhood brain tumors. They are characterized by oncogene-induced senescence (OIS) initiated and sustained by senescence-associated secretory phenotype (SASP) factors. OIS and SASP in PA are thought to be driven by a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sigaud, Romain, Selt, Florian, Hielscher, Thomas, Overbeck, Nina, Usta, Diren, Remke, Marc, Picard, Daniel, Pfister, Stephan M, Jones, David T W, Brummer, Tilman, Witt, Olaf, Milde, Till
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Low Grade Glioma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715327/ http://dx.doi.org/10.1093/neuonc/noaa222.396

Ejemplares similares

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA
por: Selt, Florian, et al.
Publicado: (2021)

LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY
por: Usta, Diren, et al.
Publicado: (2020)

LGG-29. TREATMENT FOR RECURRENT OPTIC PATHWAY PILOCYTIC ASTROCYTOMA
por: Nonaka, Masahiro, et al.
Publicado: (2020)

LGG-03. Pediatric spinal deformities concomitant with spinal cord pilocytic astrocytoma
por: Kapitancuke, Monika, et al.
Publicado: (2022)

LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma
por: Kocher, Daniela, et al.
Publicado: (2022)

LGG-09. CORRELATING GENETIC SIGNATURE OF PILOMYXOID ASTROCYTOMAS AND PILOCYTIC ASTROCYTOMAS WITH QUALITATIVE AND QUANTITATIVE MR IMAGING CHARACTERISTICS
por: Fadel, Sandra Abi, et al.
Publicado: (2020)

LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-13. PILOCYTIC ASTROCYTOMAS WITH NOVEL BRAF FUSIONS DEMONSTRATE MAPK PATHWAY ACTIVATION
por: Chatwin, Hannah, et al.
Publicado: (2021)

LGG-53. Evaluation of KIAA-BRAF1549 fusions in pilocytic astrocytoma with clinicopathological correlation
por: Dandapath, Iman, et al.
Publicado: (2022)

LGG-13. The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma
por: Li, Xiaoyu, et al.
Publicado: (2022)

LGG-07. IS BRAF ALTERATION OR A HISTOLOGIC ‘QUALIFIER’ A PREDICTOR OF OUTCOME IN PEDIATRIC PILOCYTIC ASTROCYTOMA?
por: Cler, Samuel J, et al.
Publicado: (2021)

LGG-54. DETECTION OF THE KIAA1549-BRAF FUSION GENE IN CELLS FORMING MICROVASCULAR PROLIFERATIONS IN PILOCYTIC ASTROCYTOMA
por: Yamashita, Shinji, et al.
Publicado: (2020)

LGG-01. Children with Supratentorial Midline Pilocytic Astrocytomas Exhibit Multiple Progressions and Acquisition of Neurologic Deficits over Time
por: Brossier, Nicole, et al.
Publicado: (2022)

LGG-23. EXCELLENT CLINICAL / RADIOLOGICAL RESPONSE TO BRAF INHIBITION IN A YOUNG CHILD WITH IN-OPERABLE SUPRA-SELLAR PILOCYTIC ASTROCYTOMA
por: Chapman, Stacy, et al.
Publicado: (2020)

LGG-48. PROLIFIC GROWTH OF BRAF V600E MUTANT PILOCYTIC ASTROCYTOMA WHILE ON KETOGENIC DIET: CASE REPORT
por: Batchelder, Patti, et al.
Publicado: (2020)

LGG-05. A Nine-month-old Boy with Regression of Milestones and Severe Constipation: An Unusual Case of a Spinal Pilocytic Astrocytoma
por: Offenbacher, Rachel, et al.
Publicado: (2022)

LGG-09. SENOLYTIC AGENT NAVITOCLAX TARGETS VINBLASTINE- AND MAPK INHIBITORS-INDUCED SENESCENT TUMOUR CELLS IN PAEDIATRIC LOW GRADE GLIOMAS
por: Guiho, Romain, et al.
Publicado: (2021)

LGG-64. A Phase II Study of Pegylated Interferon in Children with Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas (NCT02343224)
por: Aguilera, Dolly, et al.
Publicado: (2022)

LGG-20. CLINICAL FEATURES AND TREATMENT RESULTS FOR PEDIATRIC OPTICO-HYPOTHALAMIC ASTROCYTOMA
por: Yoshimoto, Koji, et al.
Publicado: (2020)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

LGG-49. Subependymal giant cell astrocytoma associated with a cortical tuber: A case report
por: Quinot, Valerie Anne, et al.
Publicado: (2022)

LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-16. PILOMYXOID ASTROCYTOMA OF THE CERVICAL SPINAL CORD IN A 7-YEAR-OLD ARMENIAN BOY: A CASE REPORT
por: Avagyan, Anna, et al.
Publicado: (2020)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

LGG-44. Multi-omic analysis reveals integrated signalling networks in paediatric low-grade glioma
por: Woodward, Lewis, et al.
Publicado: (2022)

LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients
por: Hardin, Emily C, et al.
Publicado: (2022)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

LGG-11. INSTITUTIONAL EXPERIENCE OF BRAF TARGETING THERAPY
por: Lola, Gino Bardi, et al.
Publicado: (2020)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

LGG-02. DRUG-CLASS SPECIFIC GENE-BASED MAPK SENSITIVITY SCORES (MSS) PREDICT SENSITIVITY TO MAPK INHIBITORS AND IDENTIFY IMMUNE INFILTRATION AS PUTATIVE TARGET IN PEDIATRIC LOW-GRADE GLIOMAS
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020)

LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial
por: Fangusaro, Jason, et al.
Publicado: (2022)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

LGG-32. CLINICAL OUTCOME OF PEDIATRIC GLIOMAS IN SINGLE INSTITUTION
por: Uchida, Hiroyuki, et al.
Publicado: (2020)

LGG-57. SIGNALLING MECHANISMS IN PAEDIATRIC LOW-GRADE GLIOMA
por: Patel, Ankit, et al.
Publicado: (2020)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

LGG-46. MOLECULAR CHARACTERIZATION OF HEMISPHERIC LOW-GRADE GLIOMAS IN CHILDREN
por: Mišove, Adéla, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d7h1bgvoeofqcqtt7innv3ge8t